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ABSTRACT 
Vecuronium is widely used to provide skeletal muscle relaxation in mechanically ventilated Intensive Care Unit patients. The absence of significant 
cardiovascular side-effects is one of its stated advantages. There have been isolated reports of Brady-dysrhythmias including sinus arrest and 
atrioventricular block when vecuronium was administered with other agents especially opioids. We report a case of cardiac arrest following 
administration of vecuronium alone in a mechanically ventilated child in the Intensive Care Unit. 
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INTRODUCTION 
Vecuronium bromide, a non-depolarizing neuromuscular blocker is 
frequently cited as a good option for muscular relaxation since it is 
free from cardiovascular activity [1]. However, several case reports 
have described severe bradycardia [2] and even cardiac arrest [3] 
after vecuronium administration. Many of these cases [4, 5] were 
associated with opioid administration. Since vecuronium has 
virtually no blocking activity on cardiac, vagus or autonomic 
ganglion, there is a tendency for bradycardia to occur in association 
with the use of opioid analgesia. Subsequent study has indicated that 
vecuronium alone does not cause bradycardia. Considering the 
various cardiovascular side-effects especially cardiac arrest, this 
drug should be used with utmost caution particularly when being 
used along with opioid analgesics. 
CASE REPORT 
This case report was prepared after taking an informed consent of 
the father. A 10 y old female child was admitted to Pediatric 
Intensive Care Unit with 1 d history of fever and altered sensorium. 
On examination, the child was afebrile, irritable but conscious, 
responsive to the command and hemodynamically stable. There was 
neither history of cardiovascular or other medical problems nor any 
drug allergy. Investigation after admission revealed the following: -
hemoglobin 9.2 gm/dl, total leukocyte count 7700/mm3
DISCUSSION 
, neutrophil 
51%, total platelet count-4.29 lac., Serum calcium-7.9 mg/dl. Serum 
electrolytes, renal function test and liver function test were normal. 
Immunochromatographic Test for malarial parasite was negative. Child 
deteriorated the next day. Glasgow Coma Scale (GCS) decreased to 7-8. A 
cerebrospinal fluid study done was normal. MRI brain was also normal. 
Arterial Blood Gas showed respiratory alkalosis with compensated 
metabolic acidosis. She was intubated for low GCS with midazolam 0.1 
mg/kg. No opioid or any other anaesthetic agent was given during the 
procedure. Post intubation, the patient was hemodynamically stable and 
maintaining saturation on 40% FiO2. She was fighting against ventilator. 
Therefore, vecuronium 1 mg/kg was given to paralyze her and prevent 
patient-ventilator dyssynchrony. She developed sudden profound 
bradycardia which was rapidly followed by cardiac arrest. Prompt 
institution of cardiopulmonary resuscitation was done. She remained 
asystolic, did not respond to any resuscitation and expired. 
Vecuronium is an aminosteroid neuromuscular blocker developed 
by Savant, Durant, Bowman and Marshall. It is an intermediately 
acting muscle relaxant outstandingly noted for its absolute 
hemodynamic stability when administered in clinical doses. 
Nevertheless, vecuronium can induce bradycardia and some cases of 
cardiac arrest after its use were found in the literature [3, 5]. The 
reason for this reduction in heart rate is poorly understood. 
Cozanitis [6] and Miller suggest that vecuronium per se is devoid of 
intrinsic bradycardic 
Sinus node exit block following administration of vecuronium has 
been reported by Yeaton. [10] Vecuronium related atrioventricular 
block has been reported by Macrae. A possible correlation between 
cardiac arrest and vecuronium bromide has been reported by 
physicians to Food & Drug Administration (FDA) and Fact Med 
between January 2004 and October 2012. A total of 1884 
vecuronium bromide drug adverse event reactions (AERS) were 
reported with the FDA during this period, of which 162 patients had 
cardiac arrest. This amounted to 8.59% of the total AERS. Drug 
Informer, an official FDA website reported 114 cases of AERS related 
to vecuronium between 2004 and 2014. Of these, 20 patients died 
due to cardiac arrest which amounted to 17.24%. 
activity. They postulate that because of lack of 
vagolytic activity of this neuromuscular agent any vagal mediated 
bradycardia is caused by other drugs (fentanyl) used simultaneously 
or by surgical stimuli. The combination of vecuronium with high 
doses of opioid produces negative chronotropic and inotropic effects 
resulting in a decrease in heart rate, cardiac output and blood 
pressure. In contrast, Inoue and colleagues [7] as well as Salmenpera 
and co-workers [8] suggested that vecuronium possesses an 
intrinsic bradycardiac activity. Vagolytic pre-anesthetic medication 
apparently protects from this undesirable effect [9]. 
CONCLUSION 
Considering the fact that vecuronium related cardiovascular 
complications especially cardiac arrest are being increasingly 
reported in the recent past, this drug can no longer be cited as 
devoid of cardiovascular effects. It is essential to be aware and 
recognize this potential complication in order to prevent possible 
death related to the vecuronium-induced cardiac arrest. Use of 
anticholinergic agent as a part of premedication or prior to 
induction of anesthesia should be seriously considered.   
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